Loading
A phase 1/2 trial of VIR-5818 run by Vir Biotechnology, Inc., now recruiting.
To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers is a phase 1/2 interventional study registered as NCT05356741 by Vir Biotechnology, Inc., with 645 participants planned, started 2022-04-13. Conditions recorded: Locally Advanced or Metastatic HER2-Expressing Cancers. Interventions recorded: VIR-5818 and pembrolizumab.
Shares Merck KGaA (EMD Serono), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sanofi, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Merck KGaA (EMD Serono) and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Merck KGaA (EMD Serono) and the tag pipeline.
Shares Sanofi and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/